150 related articles for article (PubMed ID: 7862445)
21. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
[TBL] [Abstract][Full Text] [Related]
22. Mutations in exons 5-8 of the p53 gene, independent of their type and location, are associated with increased apoptosis and mitosis in invasive breast carcinoma.
van Slooten HJ; van De Vijver MJ; Borresen AL; Eyfjörd JE; Valgardsdóttir R; Scherneck S; Nesland JM; Devilee P; Cornelisse CJ; van Dierendonck JH
J Pathol; 1999 Dec; 189(4):504-13. PubMed ID: 10629550
[TBL] [Abstract][Full Text] [Related]
23. High frequency of G/C transversion on p53 gene alterations in breast cancers from Taiwan.
Chen FM; Hou MF; Wang JY; Chen TC; Chen DC; Huang SY; Chung YS; Lin SR
Cancer Lett; 2004 Apr; 207(1):59-67. PubMed ID: 15050734
[TBL] [Abstract][Full Text] [Related]
24. p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.
Teneriello MG; Ebina M; Linnoila RI; Henry M; Nash JD; Park RC; Birrer MJ
Cancer Res; 1993 Jul; 53(13):3103-8. PubMed ID: 8319218
[TBL] [Abstract][Full Text] [Related]
25. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
[TBL] [Abstract][Full Text] [Related]
26. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
27. Distant metastases in ovarian cancer: association with p53 mutations.
Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
[TBL] [Abstract][Full Text] [Related]
28. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
29. Human epidermal cancer and accompanying precursors have identical p53 mutations different from p53 mutations in adjacent areas of clonally expanded non-neoplastic keratinocytes.
Ren ZP; Hedrum A; Pontén F; Nistér M; Ahmadian A; Lundeberg J; Uhlén M; Pontén J
Oncogene; 1996 Feb; 12(4):765-73. PubMed ID: 8632898
[TBL] [Abstract][Full Text] [Related]
30. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium.
Enomoto T; Fujita M; Inoue M; Rice JM; Nakajima R; Tanizawa O; Nomura T
Cancer Res; 1993 Apr; 53(8):1883-8. PubMed ID: 8385572
[TBL] [Abstract][Full Text] [Related]
31. Altered WAF1 genes do not play a role in abnormal cell cycle regulation in breast cancers lacking p53 mutations.
McKenzie KE; Siva A; Maier S; Runnebaum IB; Seshadri R; Sukumar S
Clin Cancer Res; 1997 Sep; 3(9):1669-73. PubMed ID: 9815858
[TBL] [Abstract][Full Text] [Related]
32. p53 mutation is a common genetic event in ovarian carcinoma.
Milner BJ; Allan LA; Eccles DM; Kitchener HC; Leonard RC; Kelly KF; Parkin DE; Haites NE
Cancer Res; 1993 May; 53(9):2128-32. PubMed ID: 8481915
[TBL] [Abstract][Full Text] [Related]
33. Mutations in the tumor suppressor gene p53 in human liver cancer induced by alpha-particles.
Andersson M; Jönsson M; Nielsen LL; Vyberg M; Visfeldt J; Storm HH; Wallin H
Cancer Epidemiol Biomarkers Prev; 1995; 4(7):765-70. PubMed ID: 8672994
[TBL] [Abstract][Full Text] [Related]
34. Gender differences in p53 mutational status in small cell lung cancer.
Tseng JE; Rodriguez M; Ro J; Liu D; Hong WK; Mao L
Cancer Res; 1999 Nov; 59(22):5666-70. PubMed ID: 10582680
[TBL] [Abstract][Full Text] [Related]
35. Identification of p53 gene mutations in breast cancers and their effects on transcriptional activation function.
Oh SJ; Jung JY; Shim SS; Im MY; Kim HD; Chung SY; Yoon JH
Mol Cells; 2000 Jun; 10(3):275-80. PubMed ID: 10901165
[TBL] [Abstract][Full Text] [Related]
36. Sequencing analysis of RNA and DNA of exons 1 through 11 shows p53 gene alterations to be present in almost 100% of head and neck squamous cell cancers.
Kropveld A; Rozemuller EH; Leppers FG; Scheidel KC; de Weger RA; Koole R; Hordijk GJ; Slootweg PJ; Tilanus MG
Lab Invest; 1999 Mar; 79(3):347-53. PubMed ID: 10092071
[TBL] [Abstract][Full Text] [Related]
37. Splice mutations in the p53 gene: case report and review of the literature.
Holmila R; Fouquet C; Cadranel J; Zalcman G; Soussi T
Hum Mutat; 2003 Jan; 21(1):101-2. PubMed ID: 12497643
[TBL] [Abstract][Full Text] [Related]
38. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
39. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
40. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor.
Thorlacius S; Börresen AL; Eyfjörd JE
Cancer Res; 1993 Apr; 53(7):1637-41. PubMed ID: 8453635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
